Arcus Biosciences CAO sells 2,562 shares
Arcus Biosciences, Inc. Chief Accounting Officer Alexander Azoy reported an open-market sale of 2,562 shares of common stock.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Arcus Biosciences, Inc. Chief Accounting Officer Alexander Azoy reported an open-market sale of 2,562 shares of common stock. The shares were sold at a weighted average price of $25.7704 per share under a pre-arranged Rule 10b5-1 trading plan. Following this transaction, Azoy directly holds 39,581 shares, which include unvested restricted stock unit grants.
Insider Trade Summary 10b5-1
Net Seller: 2,562 shares
Net Sell
1 txn
Insider
Azoy Alexander
Role
Chief Accounting Officer
Sold
2,562 shs ($66K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 2,562 | $25.7704 | $66K |
Holdings After Transaction:
Common Stock — 39,581 shares (Direct)
Footnotes (4)
- F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- F2. Consists of 2,562 shares purchased on 5/29/2026 through the Company's Employee Stock Purchase Plan.
- F3. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.67 to $25.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- F4. Includes the unvested portion of the Reporting Person's RSU grants.
Key Figures
Shares sold: 2,562 shares
Weighted average sale price: $25.7704 per share
Post-transaction holdings: 39,581 shares
+2 more
5 metrics
Shares sold
2,562 shares
Open-market sale on 2026-06-01
Weighted average sale price
$25.7704 per share
Open-market sale of common stock
Post-transaction holdings
39,581 shares
Shares directly held after sale, including unvested RSUs
Sale price range
$25.67–$25.90 per share
Range of individual trade prices within the reported sale
ESPP purchase shares
2,562 shares
Shares originally purchased on 2026-05-29 through Employee Stock Purchase Plan
Key Terms
Rule 10b5-1 trading plan, Employee Stock Purchase Plan, weighted average price, RSU grants
4 terms
Rule 10b5-1 trading plan regulatory
"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Employee Stock Purchase Plan financial
"Consists of 2,562 shares purchased on 5/29/2026 through the Company's Employee Stock Purchase Plan."
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
weighted average price financial
"The price reported in column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
RSU grants financial
"Includes the unvested portion of the Reporting Person's RSU grants."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Arcus Biosciences (RCUS) report for Alexander Azoy?
Arcus Biosciences reported that Chief Accounting Officer Alexander Azoy sold 2,562 shares of common stock in an open-market transaction. The sale was executed under a pre-arranged Rule 10b5-1 trading plan at a weighted average price of $25.7704 per share.
Was the Arcus Biosciences (RCUS) insider sale done under a Rule 10b5-1 plan?
Yes. The filing specifies that the sales were effected under a Rule 10b5-1 trading plan adopted by Alexander Azoy. Such plans pre-schedule trades, which can make the timing of transactions more routine and less indicative of short-term views on the company’s share price.
What does the footnote about the Employee Stock Purchase Plan mean for RCUS?
One footnote explains that the 2,562 shares sold had been purchased on May 29, 2026 through the company’s Employee Stock Purchase Plan. This indicates the shares came from a company-sponsored program that allows employees to buy stock, before later being sold in the reported transaction.
What price range did the Arcus Biosciences (RCUS) insider sale cover?
The filing notes that the reported weighted average price of $25.7704 reflects multiple trades between $25.67 and $25.90 per share. The insider has committed to provide full breakdowns of share amounts at each price level upon request to the issuer, shareholders, or SEC staff.
AI-generated analysis. How Rhea-AI works. Not financial advice.
